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A B S T R A C T
E-cigarettes (EC) are now the most popular quit aid in England but their eﬀectiveness for cessation if oﬀered at a
pharmacy has not been tested. Here we test the eﬀectiveness of oﬀering an e-cigarette with and without nicotine
replacement therapy (NRT) on 4–6-week quit rates in adult smokers seeking support from a community phar-
macy. A between subject, six-week, prospective, cohort design. 115 smokers (female= 74; M age= 46.37,
SD=13.56) chose either an EC, EC+NRT or NRT alone, alongside standard behavioural support. Smokers
opting for an EC alone or an EC+NRT were more likely to report complete abstinence from smoking at
4–6weeks (62.2% and 61.5% respectively) compared to NRT alone (34.8%). An EC intervention was sig-
niﬁcantly more eﬀective for smoking cessation than NRT in this community pharmacy. The results for e-ci-
garettes appear positive but with the caveat that participants chose their own products which may have in-
troduced bias.
1. Introduction
Cigarette smoking is the single most important cause of premature
mortality in the world and quitting is known to rapidly reduce the risk
of lung cancer, cardiovascular disease, stroke, chronic lung disease and
other cancers (The health beneﬁts of smoking cessation, 1990; World
Health Organization, 2008). Smoking prevalence has steadily declined
in the UK with fewer young people starting and more adults quitting
(Oﬃce for National Statistics (ONS), 2017) however, health care bud-
gets for smoking cessation are being reduced limiting the choices
available to smokers (ASH Action on Smoking and Health & Cancer
Research UK, 2019).
E-cigarettes (EC) are currently the most popular quit aid for smokers
in England (West, Proudfoot, Beard & Brown, 2019) and a recent trial in
English Stop Smoking Services (SSS) demonstrated that participants
provided with an EC were almost twice as likely to quit than those
prescribed Nicotine Replacement Therapy (NRT) (Hajek et al., 2019).
The context in which ECs are oﬀered and the type of support received is
likely to inﬂuence use and potentially cessation.
Pharmacies can be considered an important community-based front-
line service in which to engage with smokers. They have been providing
stop smoking support in the UK for many years, traditionally through
over-the-counter or prescription of NRT and in some cases, behavioural
support. Although the evidence on cessation rates associated with
pharmacies is limited, quit success is traditionally low via this method,
22.5% at 4-weeks (Bauld et al., 2010; Sinclair, Bond, & Stead, 2004).
Furthermore, pressure on UK healthcare budgets has led to restrictions
on the number of NRT prescriptions available to some smokers, many
pharmacies (including the one in this study) can only oﬀer one form of
NRT (due to restrictions on reimbursement), although recent evidence
suggests more than one can increase eﬃcacy (Lindson et al., 2019).
Oﬀering an EC within a pharmacy setting may augment cessation rates,
and a Cochrane review concluded that as pharmacists are trained in
smoking cessation and provide counselling, they still have a positive
role to play in cessation (Sinclair et al., 2004) and are cost-eﬀective
(Bauld et al., 2010).
Presented here is an exploratory study which measured the eﬀec-
tiveness of oﬀering an EC on cessation within a community pharmacy
setting in Hertfordshire, England compared with the pharmacy's usual
care NRT protocol. Smokers were oﬀered a range of cessation treat-
ments, including an EC. The primary outcome was deﬁned as 4–6-week
self-report smoking cessation rates.
2. Methods
One hundred and ﬁfteen smokers (female= 74; M age=46.37,
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SD=13.56) were recruited through pharmacy counter staﬀ, digital and
non-digital displays in the pharmacy window and social media
(Facebook), throughout 2017–2018. In line with usual care standard,
inclusion criteria were self-reported smoker veriﬁed by CO 7≥ parts
per million (ppm) and aged 18 years or over. Two of the participants
were pregnant (both in EC condition).
A non-randomised prospective cohort study with a between subject
design was employed. Participants could choose EC, NRT or a combi-
nation of both, thus treatment condition (NRT×NRT with EC× EC
alone) was the independent factor. In line with the pharmacy's usual
care protocol, the primary outcome was self-reported total smoking
abstinence at 4–6weeks follow up. CO validation was taken where
possible.
Participants were considered non-quitters if they i) dropped out, ii)
reported not-quitting, iii) dual used (i.e. smoked and used the EC), iv)
CO≥7 ppm.
Basic demographic information was obtained from all smokers (age,
gender, employment status), current smoking status was ascertained by
self-report and CO breath test. Cigarette dependence was measured
using the Fagerstrom Test of Cigarette Dependence (FTCD; 10).
NRT consisted of a choice of gum (fruit ﬂavoured, 2mg, 4mg or
6mg); lozenge (mint or fruit, 1 mg, 2mg, 4mg); inhalator (15mg);
mouth spray 1mg /spray or patch (10mg, 15mg or 25mg).
A simple pod-based EC (Mylo brand) with 18mg/mL nicotine con-
centration liquid was oﬀered with a choice of e-liquid ﬂavours.
3. Results
Table 1 presents demographic, survey and outcome data for in-
dividuals in all conditions.
Smokers opting for an EC alone or with NRT were more likely to
have reported complete abstinence from smoking at 4–6weeks (23/37
[62.2%] and 8/13 [61.5%] respectively) compared to NRT alone (22/
65 [34.8%]).
Compared with those using NRT, the odds of quitting with an EC
increased by 3.23 and the odds of quitting with EC+NRT increased by
3.14.
4. Discussion
An EC intervention was more eﬀective for smoking cessation than
NRT in this community pharmacy; at 4–6weeks, for every one person
who quit successfully with NRT, 3.23 quit successfully with EC.
In England, although ECs are now the number one quit aid for
smokers (West et al., 2019), more evidence is needed to understand the
conditions under which they can assist quitting. These results come
from a small sample with a short follow-up, but they add to a growing
body of evidence (in England at least) that ECs are eﬀective in helping
smokers to quit. However, long-term abstinence is diﬃcult to achieve;
an observational study by Bauld et al. (2010) saw 4-week pharmacy CO
validated quit rates with NRT fall from 22.5% to 3.6% at 12-months.
Thus, to be reassured of the chance of relapse, it is recommended that
longer term (6 and 12-month) follow up rates are measured with as
high a rate of CO veriﬁed quit status data as feasible (West, Hajek,
Stead, & Stapleton, 2005).
There are several limitations to this study. This was not a rando-
mised trial and smokers were able to choose their product after con-
sultation which is open to bias.
Those choosing an EC may present with diﬀerent motivations, be-
liefs and attitudes towards smoking and the use of ECs, e.g., previous
bad experiences with NRT, knowing other EC users, incentivised by a
free and novel product, which may have inﬂuenced motivation to quit
during this attempt.
5. Conclusion
Oﬀering an EC within a pharmacy shows early signs of being ef-
fective for smoking cessation though more work is needed to determine
whether these initial promising eﬀects are sustained over a longer
period.
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